Last reviewed · How we verify
NCT06635421: EXPAND
The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV
trial testing Model of care delivery for long-acting injectable ART in HIV I Infection in 164 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | MetroHealth Medical Center |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 164 |
| Start date | 1 November 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Model of care delivery for long-acting injectable ART
Conditions studied
- HIV I Infection — all drugs for HIV I Infection →
Sponsor
MetroHealth Medical Center
Who can join
18 and older, any sex, with HIV I Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of The EXPAND study is to develop and pilot a pharmacist led model of medication delivery. Following a co-design phase, patients may receive injections at satellite pharmacies by a licensed pharmacist. The acceptability, appropriateness, and feasibility of this approach and standard in clinic administration by a nurse will be assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06635421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV I Infection
Currently open trials in the same condition.
- NCT06799338 — Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France · recruiting
- NCT06834113 — Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal o · NA · recruiting
- NCT07202936 — Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe · recruiting
- NCT05947890 — Evaluating the Safety and Immunogenicity of MTBVAC · Phase 2 · recruiting
- NCT05110963 — Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments · NA · active not recruiting
Other MetroHealth Medical Center trials
Trials by the same sponsor.
- NCT06734026 — Multimodal, Enriched Environment for Rehabilitation in Chronic Traumatic Brain Injury · NA · recruiting
- NCT06664892 — Ultrahypofractionated Whole Breast Radiation Following Chemotherapy · NA · not yet recruiting
- NCT06788795 — Effectiveness of a Wearable Hydration Device · Phase 2 · not yet recruiting
- NCT06836739 — At-Home Genital Nerve Stimulation for SCI Bowel · NA · recruiting
- NCT06113965 — Neural Operant Conditioning · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06635421 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MetroHealth Medical Center
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06635421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing